Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT00664313
PHASE1/PHASE2

TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

Sponsor: Centers for Disease Control and Prevention

View on ClinicalTrials.gov

Summary

This study evaluated the safety and tolerability of low-dose linezolid (600 mg once daily) administered for 16 weeks as part of an optimized background regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB).

Official title: TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2009-04

Completion Date

2010-09

Last Updated

2026-07-06

Healthy Volunteers

No

Interventions

DRUG

Linezolid

600 mg po daily for 112 doses (16 weeks)

DRUG

Placebo

Placebo given daily for 112 doses (16 weeks)

Locations (1)

King George V Hospital

Durban, South Africa